OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Employees - 3, CEO - Dr. Gary S. Jacob Ph.D., Sector - Healthcare, Country - GB, Market Cap -

Altman ZScore(max is 10): -71.16, Piotroski Score(max is 10): 1, Working Capital: $-7227790, Total Assets: $2828858, Retained Earnings: $-145202000, EBIT: -8979, Total Liabilities: $10054490, Revenue: $0

AryaFin Target Price - $0.02 - Current Price $ - Analyst Target Price $